S. H. Swerdlow, E. Campo, S. A. Pileri, N. L. Harris, H. Stein et al., The 2016 revision of the World Health Organization classi cation of lymphoid neoplasms, Blood, vol.127, issue.20, pp.2375-90, 2016.

S. J. Denardo, G. L. Denardo, O. Grady, L. F. Macey, D. J. Mills et al., Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies, Int J Biol Markers, vol.2, issue.1, pp.49-53, 1987.

O. W. Press, J. P. Leonard, B. Coif-er, R. Levy, and J. Timmerman, Immunotherapy of non-Hodgkin's lymphomas, Hematology Am Soc Hematol Educ Program, pp.221-261, 2001.

B. D. Cheson, Radioimmunotherapy of Non-Hodgkin lymphomas, Blood, vol.101, issue.2, pp.391-399, 2003.

J. Pouget, C. Lozza, E. Deshayes, V. Boudousq, and I. Navarro-teulon, Introduction to radiobiology of targeted radionuclide therapy, Front Med (Lausanne), vol.2, issue.4, p.12, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01934653

J. Pouget, I. Navarro-teulon, M. Bardies, N. Chouin, G. Cartron et al., Clinical radioimmunotherapy-the role of radiobiology, Nat Rev Clin Oncol, vol.8, issue.12, pp.720-754, 2011.

M. Bourgeois, C. Bailly, M. Frindel, F. Guerard, M. Cherel et al., Radioimmunoconjugates for treating cancer: recent advances and current opportunities, Expert Opin Biol Ther, vol.17, issue.7, pp.813-822, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01635514

S. J. Denardo, G. L. Denardo, O. Grady, L. F. Hu, E. Sytsma et al., Treatment of B cell malignancies with131I Lym-1 monoclonal antibodies, Int J Cancer Suppl, vol.41, issue.S3, pp.96-101, 1988.

M. P. Chao, Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphomanovel and emerging therapies, Cancer Manag Res, vol.5, pp.251-69, 2013.

M. Merli, A. Ferrario, M. Maf-oli, L. Arcaini, and F. Passamonti, Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma, Expert Opin Investig Drugs, vol.24, issue.7, pp.897-912, 2015.

J. M. Bennett, M. S. Kaminski, J. P. Leonard, J. M. Vose, A. D. Zelenetz et al., Assessment of treatmentrelated myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab, Blood, vol.105, issue.12, pp.4576-82, 2005.

S. J. Horning, A. Younes, V. Jain, S. Kroll, J. Lucas et al., Ef cacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab, J Clin Oncol, vol.23, issue.4, pp.712-721, 2005.

K. Hohloch, H. K. Lankeit, P. L. Zinzani, C. W. Scholz, M. Lorsbach et al., Radioimmunotherapy for rst-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network, Eur J Nucl Med Mol Imaging, vol.41, issue.8, pp.1585-92, 2014.

K. Hohloch, Radioimmunotherapy of lymphoma: an underestimated therapy option, Lancet Haematol, vol.4, issue.1, pp.6-7, 2017.

K. Hohloch, A. B. Delaloye, C. Windemuth-kieselbach, J. Gómez-codina, W. Linkesch et al., Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the International Radioimmunotherapy Network, J Nucl Med, vol.52, issue.9, pp.1354-60, 2011.

M. S. Czuczman, C. Emmanouilides, M. Darif, T. E. Witzig, L. I. Gordon et al., Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy, J Clin Oncol, vol.25, issue.27, pp.4285-92, 2007.

C. Bodet-milin, Radioimmunotherapy of B-cell nonHodgkin's lymphoma, Front Oncol, vol.3, p.177, 2013.

F. Morschhauser, J. Radford, A. Van-hoof, U. Vitolo, P. Soubeyran et al., Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after rst remission in advanced follicular lymphoma, J Clin Oncol, vol.26, issue.32, pp.5156-64, 2008.

F. Morschhauser, J. Radford, A. Van-hoof, B. Botto, A. Rohatiner et al., 90Yttrium-ibritumomab tiuxetan consolidation of rst remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median followup of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial, J Clin Oncol, vol.31, issue.16, pp.1977-83, 2013.

R. M. Sharkey, A. Brenner, J. Burton, G. Hajjar, S. P. Toder et al., Radioimmunotherapy of nonHodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?, J Nucl Med, vol.44, issue.12, pp.2000-2018, 2003.

O. Lindén, C. Hindorf, E. Cavallin-ståhl, W. A. Wegener, D. M. Goldenberg et al., Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab, Clin Cancer Res, vol.11, issue.14, pp.5215-5237, 2005.

C. Bodet-milin, F. Kraeber-bodéré, B. Dupas, F. Morschhauser, T. Gastinne et al., Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in nonHodgkin's lymphoma by 18F-uorodeoxyglucose positron emission tomography, Haematologica, vol.93, issue.3, pp.390-397, 2008.

F. Morschhauser, F. Kraeber-bodéré, W. A. Wegener, J. Harousseau, M. Petillon et al., High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma, J Clin Oncol, vol.28, issue.23, pp.3709-3725, 2010.

F. Kraeber-bodéré, A. Pallardy, H. Maisonneuve, L. Campion, A. Moreau et al., Consolidation anti-CD22 fractionated radioimmunotherapy with (90)Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial, Lancet Haematol, vol.4, issue.1, pp.35-45, 2017.

A. Kolstad, U. Madsbu, M. Beasley, M. Bayne, T. Illidge et al., Lymrit 37-01: updated results of a phase I/II study of 177Lu-Lilotomab satetraxetan, a novel CD37-targeted antibody-radionuclideconjugate in relapsed NHL patients, Hematol Oncol, vol.35, pp.269-70, 2017.

C. Stokke, J. Blakkisrud, A. Løndalen, J. Dahle, A. Martinsen et al., Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan signi cantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients, Eur J Nucl Med Mol Imaging, vol.45, issue.7, pp.1233-1274, 2018.

J. Blakkisrud, A. Løndalen, J. Dahle, S. Turner, H. Holte et al., Red marrow-absorbed dose for non-Hodgkin lymphoma patients treated with 177Lu-Lilotomab satetraxetan, a novel anti-CD37 antibody-radionuclide conjugate, J Nucl Med, vol.58, issue.1, pp.55-61, 2017.

J. Blakkisrud, A. Løndalen, A. Martinsen, J. Dahle, J. E. Holtedahl et al., Tumor-absorbed dose for non-Hodgkin lymphoma patients treated with the anti-CD37 antibody radionuclide conjugate 177Lu-Lilotomab Satetraxetan, J Nucl Med, vol.58, issue.1, pp.48-54, 2017.

L. Aloj, D. 'ambrosio, L. Aurilio, M. Morisco, A. Frigeri et al., Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extradomain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma, Eur J Nucl Med Mol Imaging, vol.41, issue.5, pp.867-77, 2014.

D. A. Rizzieri, G. Akabani, M. R. Zalutsky, R. E. Coleman, S. D. Metzler et al., Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma, Blood, vol.104, issue.3, pp.642-650, 2004.

G. Gritti, A. Gianatti, F. Petronzelli, D. Santis, R. Pavoni et al., Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identies a new target for radioimmunotherapy, Oncotarget, vol.9, issue.11, pp.9766-75, 2018.

S. V. Govindan, D. M. Goldenberg, S. E. Elsamra, G. L. Grif-ths, G. L. Ong et al., Radionuclides linked to a CD74 antibody as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters, J Nucl Med, vol.41, issue.12, pp.2089-97, 2000.

M. Zhang, Z. Yao, H. Patel, K. Garmestani, Z. Zhang et al., Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1, Proc Natl Acad Sci, vol.104, issue.20, pp.8444-8452, 2007.

A. Moss, J. Gudas, T. Albertson, N. Whiting, and C. Law, Abstract 104: preclinical microPET/CT imaging of 89Zr-Df-SGN-35 in mice bearing xenografted CD30 expressing and non-expressing tumors, Cancer Res, vol.74, p.104, 2014.

S. N. Rylova, D. Pozzo, L. Klingeberg, C. Tönnesmann, R. Illert et al., Immuno-PET imaging of CD30-positive lymphoma using 89Zr-desferrioxamine-labeled CD30-speci c AC-10 antibody, J Nucl Med, vol.57, issue.1, pp.96-102, 2016.

D. J. Green, S. O'steen, Y. Lin, M. L. Comstock, A. L. Kenoyer et al., CD38-bispeci c antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies, Blood, vol.131, issue.6, pp.611-631, 2018.

D. A. Vallera, M. Elson, M. W. Brechbiel, K. E. Dusenbery, L. J. Burns et al., Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody, Cancer Biother Radiopharm, vol.19, issue.1, pp.11-23, 2004.

G. L. Denardo, J. Schlom, D. J. Buchsbaum, R. F. Meredith, J. A. O'donoghue et al., Rationales, evidence, and design considerations for fractionated radioimmunotherapy, Cancer, vol.94, issue.4, pp.1332-1380, 2002.

T. M. Illidge, S. Mayes, R. Pettengell, A. T. Bates, M. Bayne et al., Fractionated 90 Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/ BNLI criteria, J Clin Oncol, vol.32, issue.3, pp.212-220, 2014.

C. W. Scholz, A. Pinto, W. Linkesch, O. Lindén, A. Viardot et al., Yttrium-ibritumomab-tiuxetan as rst-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial, J Clin Oncol, vol.90, issue.3, pp.308-321, 2013.

M. Kameswaran, U. Pandey, C. Dhakan, K. Pathak, V. Gota et al., Synthesis and preclinical evaluation of (177)Lu-CHX-A?-DTPA-rituximab as a radioimmunotherapeutic agent for nonHodgkin's lymphoma, Cancer Biother Radiopharm, vol.30, issue.6, pp.240-246, 2015.

G. L. Denardo, New directions in radioimmunotherapy of non-Hodgkin's lymphoma, Clin Lymphoma, vol.5, issue.1, p.4, 2004.

G. L. Denardo, S. J. Denardo, D. L. Kukis, O. Donnell, R. T. Shen et al., Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study, Anticancer Res, vol.18, issue.4B, pp.2779-88, 1998.

G. L. Denardo, S. J. Kennel, J. A. Siegel, and S. J. Denardo, Radiometals as payloads for radioimmunotherapy for lymphoma, Clin Lymphoma, vol.5, issue.1, pp.5-10, 2004.

C. G. England, L. Rui, and W. Cai, Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies, Eur J Nucl Med Mol Imaging, vol.44, issue.3, pp.517-549, 2016.

S. M. Knowles and A. M. Wu, Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology, J Clin Oncol, vol.30, issue.31, pp.3884-92, 2012.

O. C. Boerman and W. Oyen, Immuno-PET of cancer: a revival of antibody imaging, J Nucl Med, vol.52, issue.8, pp.1171-1173, 2011.

G. Van-dongen, G. Visser, M. N. Lub-de-hooge, E. G. De-vries, and L. R. Perk, Immuno-PET: a navigator in monoclonal antibody development and applications, Oncologist, vol.12, issue.12, pp.1379-89, 2007.

A. Natarajan and S. S. Gambhir, Radiation dosimetry study of [(89)Zr]rituximab tracer for clinical translation of B cell NHL imaging using positron emission tomography, Mol Imaging Biol, vol.17, issue.4, pp.539-586, 2015.

J. T. Yoon, M. S. Longtine, B. V. Marquez-nostra, and R. L. Wahl, Evaluation of next-generation anti-CD20 antibodies labeled with zirconium 89 in human lymphoma xenografts, J Nucl Med, vol.59, issue.8, pp.1219-1243, 2018.